PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of halLink to Publisher's site
 
Arch Neurol. Author manuscript; available in PMC May 1, 2014.
Published in final edited form as:
PMCID: PMC4004919
HALMSID: HALMS728999
INSERM Subrepository
Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals
Audrey Perrotin,1* Elizabeth C. Mormino,2 Cindee M. Madison,2 Amynta O. Hayenga,2 and William J. Jagust2,3
1Neuropsychologie Cognitive et Neuroanatomie Fonctionnelles de la Mémoire INSERM : U923, CHU Caen, Université de Caen Basse-Normandie, Ecole Pratique des Hautes Etudes, Cyceron, Boulvard Henri Becquerel, BP5229, 14074 Caen Cedex 5, FR
2HWNI, The Helen Wills Neuroscience Institute University of California, Berkeley, 3210F Tolman Hall MC 3192 Berkeley, CA 94720-3192, US
3The Life Sciences Division Lawrence Berkeley National Laboratory, University of California, Berkeley, Berkeley, CA, US
* Correspondence should be addressed to: Audrey Perrotin ; perrotin/at/cyceron.fr
Background
Subjective cognitive impairment (SCI) as an early clinical manifestation in Alzheimer disease (AD) is a central and highly debated question.
Objective
To study the relationship between subjective cognition and the neuropathological hallmark of AD, amyloid-beta (Aβ) deposition, imaged with [11C]-Pittsburg compound B (PiB) - positron emission tomography (PET), in normal elderly individuals.
Design
Cross-sectional analysis.
Subjects
Forty-eight cognitively normal elderly subjects (11 with high PiB uptake and 28 with low PiB uptake) were included. All underwent clinical and neuropsychological evaluations and MRI and PET scanning.
Results
High PiB subjects showed significantly lower performance than low PiB subjects on an episodic memory measure, and were less confident about their general memory abilities when required to evaluate themselves relative to other people of the same age. High and low PiB groups did not differ on the accuracy of their cognitive self-reports compare to objective cognitive performance. General memory self-reports from the whole group were significantly correlated to regional PiB uptake in the right medial prefrontal cortex (PFC)/anterior cingulate cortex (ACC) and in the right precuneus/posterior cingulate cortex (PCC). Reduced confidence about memory abilities was associated with greater PiB in these brain regions. All results are independent of demographic variables and depressive affects.
Conclusions
Our findings suggest that a decrease of self-confidence about memory abilities in cognitively normal elderly subjects is related to the neuropathological hallmark of AD measured with PiB-PET imaging. The relevance of SCI in the early stages of the AD pathological process is addressed.
Keywords: Aged, Aged, 80 and over, Aging, physiology, Amyloid beta-Peptides, metabolism, Aniline Compounds, Biological Markers, Cerebral Cortex, radionuclide imaging, Cognition, physiology, Cognition Disorders, metabolism, psychology, radionuclide imaging, Cohort Studies, Female, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Memory, physiology, Middle Aged, Neuropsychological Tests, Positron-Emission Tomography, Prefrontal Cortex, radionuclide imaging, Radiopharmaceuticals, Reference Values, Thiazoles
Subjective cognitive impairment (SCI) is an early behavioral manifestation in the course of Alzheimer disease (AD) which may precede objective mild cognitive impairment (MCI) in the continuum of disease progression[14]. Cognitive complaints in older adults as a predictor of future dementia[5,6]remains controversial. This disagreement is partially explained by confounding affective and personality factors that may be unrelated to development of AD[7,8]. Thus, to test the validity of cognitive complaints as an early sign of AD, it is of interest to evaluate subjective cognition in relation to specific markers of AD pathology.
Amyloid-beta (Aβ) peptide deposition in senile plaques is a key neuropathological feature of AD[9]and may be the initiating event of the Alzheimer’s pathological cascade[10,11]. Brain imaging offers the opportunity to visualize and quantify this pathology in vivo, using positron emission tomography (PET) with the [11C]-PiB (Pittsburgh compound B) radiotracer which binds specifically to fibrillar Aβ plaques. Elevated PiB has been shown in AD and MCI patients[12,13], as well as in about 30% of cognitively normal older subjects[14,15]. Elevated PiB uptake in AD is typically found in the posterior cingulate cortex (PCC) and medial prefrontal cortex (MPFC)[14].
The study aimed to investigate the relationship between subjective cognition in the healthy elderly population and PiB status. Although the present study did not specifically recruit SCI subjects, previous work in SCI has shown brain structural and functional abnormalities that mimic those commonly observed in AD (i.e. decreased grey matter volume[1621], cerebral metabolism reduction[22,23]), as well as increased genetic risk for AD (such as apolipoprotein E ε4 allele[24,25]). Furthermore, postmortem studies have consistently observed that memory complaints in healthy older adults were associated with amyloid in autopsied tissues at death[26,27]. Using amyloid imaging, two recent studies have examined PiB retention in people with SCI. Rodda et al.[28]studied amyloid load in 5 subjects with memory complaints and observed that only 1 subject had significantly increased PiB uptake relative to controls. Chételat et al.[29]reported that the proportion of subjects classified as PiB positive in an SCI group (39%) was higher than in a control group (29%), although this difference did not reach significance.
Subjective cognition or cognitive self-awareness is a metacognitive monitoring function enabling the evaluation of one’s own cognitive system. Metacognition literature usually distinguishes two forms of monitoring: off-line versus on-line monitoring. Off-line cognitive monitoring corresponds to self-assessment of global cognitive functioning, and covers declarative knowledge about one’s own cognitive abilities[30]. On-line monitoring involves ongoing assessment of one’s performance within the context of a particular cognitive task[31]. Whereas previous studies examining the relationships of SCI with AD biomarkers have used general offline monitoring assessment, the present study addresses this association using different subcomponents of metacognitive monitoring.
In this study, we investigate whether subjective cognition in a group of cognitively normal elderly individuals is associated with the neuropathological hallmark of AD, Aβ. To this end, subjective cognition was assessed with off-line monitoring measures, i.e. self-assessment of one’s daily memory abilities using a general question addressing overall memory functioning, as well as with on-line monitoring measures, i.e. self-assessment of one’s performance during a specific cognitive task using a postdiction of performance procedure. Aβ deposition was assessed using PiB uptake with PET imaging. Based upon results from postmortem studies, we hypothesized that subjective cognition would be associated with early markers of AD in in vivo brain. Specifically, cognitively normal and non depressed subjects with high PiB uptake would report more cognitive complaints. In terms of regional brain localization, it is expected that relationships between PiB uptake and subjective cognition measures would be the highest in regions where amyloid deposition is typical (i.e. greater and earlier) in the AD pathological process.
Subjects
Forty-eight cognitively normal elderly subjects were tested in the present study. There were 31 women and 17 men ranging in age from 61–88 years (mean age=73.48 ±5.91 years), with a mean education level of 17.29 years (±1.90) and a mean Mini-Mental State Examination (MMSE) score of 29 (±1.11). These subjects come from the Berkeley Aging Cohort Study (BACS), a pool of community-dwelling healthy volunteers over 60 years old residing in the San Francisco Bay Area. BACS subjects were recruited through advertisements in senior centers and local newspapers requesting participation in a research project investigating aging and changes in cognitive function. The study was approved by the local ethics committee and subjects gave written informed consent. All subjects provided data on medical history, underwent a neuropsychological test battery, and interviews about functional ability and lifestyle. Eligibility criteria include independent daily living, absence of any medical, psychiatric or neurologic condition that might affect brain structure and functioning, including depression (e.g. Geriatric Depression Scale (GDS) in normal range), normal performance on cognitive tests, absence of psychoactive medication use, and absence of sensory impairment that might interfere with the cognitive testing. From the sample of 185 BACS subjects, 48 met inclusion criteria and agreed to both MRI and PiB PET scanning for this study. The mean time between behavioral testing and PET imaging was about 6 months (mean time=182 ±160 days).
Behavioral data
Cognitive measures
All subjects underwent a detailed neuropsychological testing battery which included episodic memory assessment with the California Verbal Learning Test-Second Edition[32](CVLT-II) and the Visual Reproduction subtest of the Wechsler Memory Scale-Revised[33](WMS-R), executive abilities measurement with the Stroop Color Word Test[34], the Digit Span forward and backward subtests of the Wechsler Adult Intelligence Scale-Revised[35](WAIS-R), the Listening Span test[36], and fluency measures with the Letter Fluency test of the Controlled Word Association Test[37](COWAT) and the Category Fluency test[37].
Subjective cognition measures
Off-line memory monitoring. General memory self-reports were measured by asking subjects to respond to two global questions about their general daily memory functioning; one relative to other people of the same age, the other relative to 20 years ago. For each question the participant gave her/his reply using a 4-point ordinal scale: “1-Better”, “2-About the same”, “3-A bit worse”, “4-Much worse”. On-line cognitive monitoring. Global postdictions of performance were solicited after the completion of each of the 7 cognitive tasks reported above. The participant was asked to estimate performance on the test (i.e. postdiction) relative to other people of the same age, sex and similar education. The participant rated her/his own performance relative to normative data on a percentile response scale (from “worse” to “better than other people”). Based upon high correlation amongst the 7 postdiction scores, a single postdiction composite score was computed for each subject by averaging their 7 postdiction scores (see eMethods).
Brain imaging
MRI
All subjects underwent high resolution MRI scans on a 1.5-T Magnetom Avanto system (Siemens Inc., Iselin, NJ) at the Lawrence Berkeley National Laboratory (LBNL) with a 12 channel head coil run in triple mode. Three high-resolution structural T1-weighted volumetric magnetization prepared rapid acquisition gradient echo (MP-RAGE) scans were collected axially for each subject (TR/TE/TI=2110/3.58/1100 ms, flip angle=15°, with 1.00x1.00 mm2 in-plane resolution and 1.00 mm slice thickness).
PET imaging
Radiochemical synthesis, image acquisition and processing
Radiosynthesis of [11C]-PiB was completed at the LBNL Facility using a previously published protocol[38]. PET scans were performed using a Siemens ECAT EXACT HR PET scanner at LBNL in 3D acquisition mode. [11C]-PiB was injected into an antecubital vein, and a 90-min dynamic acquisition as well as a 10-min transmission scan for attenuation correction were collected. PiB PET image processing was implemented using the Statistical Parametric Mapping software (SPM2; Welcome Department of Cognitive Neurology, University College, London, UK). PiB frames were realigned and the mean image was coregistered to the individual’s MRI scan. PiB PET distribution volume ratio (DVR) images were created using Logan graphical analysis (with frames corresponding to 35–90 min post-injection[39,40]and a cerebellum reference region[41]). PiB DVR images were partial volume correction (PVC)[42]. Further details about image acquisition and processing are available in the eMethods.
ROI analysis
An MRI-based automated ROI technique was used to extract regional PiB data using the FreeSurfer software package (http://surfer.nmr.mgh.harvard.edu/). These FreeSurfer processing steps are detailed in Mormino et al.[43]and in eMethods. In brief, subcortical and cortical ROIs spanning the entire brain were defined in each subject’s native space[44,45]. Global PiB uptake index was produced by combining multiple cortical ROIs which are known to be associated with amyloid deposition early in AD[14]. In addition, regional PiB indices were derived from five a priori ROIs: medial PFC/ACC, lateral PFC, precuneus/PCC/ICC, medial temporal lobe and lateral temporal lobe.
PiB group classification
Subjects of the sample were classified as high or low PiB on the basis of their global PiB uptake level using a cut off approach described by Aizenstein et al.[46]. Subjects within 2.5% above or below the cutoff value were excluded from analysis.
Statistical analyses
The relationships between PiB uptake and subjective cognition were analyzed in two ways using rank-order non-parametric statistical methods. In a first step, the dichotomous PiB measure (high versus low PiB) was used to evaluate group differences on variables of interest. For this, two-sample Mann-Whitney U tests were used for all measures except for the bi-categorical variable (i.e. gender) that was analyzed with a chi-squared test. In a second step, continuous PiB measures were used to evaluate the relationship between regional values of PiB uptake and subjective cognition measures, using Spearman’s rank correlations. Demographic variables (age, gender and education) were controlled for in each analysis, as well as a measure of depression (GDS) in analyses involving metacognitive measures. All statistical analyses were conducted using computerized statistical software (Statistica 8.0, StatSoft inc., Tulsa, OK), with an alpha level of 0.05 for statistical significance.
PiB group differences
The Aizenstein method revealed a cut off of 1.460, classifying 11 subjects as high and 28 as low PIB (9 subjects within 2.5% of this value were excluded). PiB group differences on demographic variables, cognitive and metacognitive measures are presented in the Table 1.
Table 1
Table 1
PiB group differences on demographic variables, cognitive and metacognitive measures.
Demographic measures
No significant differences were observed between high and low PiB groups on the demographic variables.
Cognitive measures
High PiB subjects performed worse than low PIB subjects on a single episodic memory measure–the immediate recall of the CVLT, and this effect remained significant after controlling for demographics (F(1, 33)=7.101, MS=1068.195, p=0.012).
Metacognitive measures
High and low PiB subjects differed on an off-line monitoring measure –the general memory self-reports relative to other people, and this effect remained significant after controlling for demographics and GDS, using an ANCOVA for ordinal multinomial distributions (Wald (1)=4.351, SE=0.243, p=0.037). Specifically, subjects with high PiB uptake felt less confident about their memory than low PiB subjects (see Figure 1). More specifically, 44% of the low PiB subjects felt that they had better memory than most people while 9% of the high PiB subjects made this assessment. A two-proportion z-test indicated that this difference is significant (p=0.039). No significant PiB group effect was observed on the off-line monitoring measure that assessed memory relative to their abilities 20 years before, or on on-line monitoring measures.
Figure 1
Figure 1
Proportion of self-reports to the general question about one’s memory abilities relative to other people of the same age, according to the PiB group.
Correlations between subjective and objective cognition
To explore how subjective cognition relates to actual performance, relationships between metacognitive judgments and objective scores within each PiB group was examined (see eResults, eFigure 1). No significant differences in the strength of these within group correlations were identified across metacognitive measures (i.e. there was no effect of PIB status on the relationship between subjective and objective performance).
Correlations between regional PiB uptake and subjective cognition
We explored the relationship between the subjective cognition measure that was related to PIB status (the general memory self-reports relative to other people), and regional PiB uptake as a continuous variable in specific ROIs. Table 2 summarizes the correlations between PiB and general memory self-reports relative to other people for the five examined ROIs, controlling for age, gender, education and GDS. Significant positive correlations were noted in the R medial PFC/ACC as well as in the R precuneus/PCC/ICC. Thus, this ROI approach suggests the pattern of PiB uptake in the R medial anterior and posterior cortices is related to reduced general memory ability confidence relative to other people of the same age.
Table 2
Table 2
Correlations between PiB and general memory self-reports relative to other people of the same age, for the five key ROIs (effects of age, gender, education and GDS were removed).
The present study highlights that subjective cognition may be associated with the neuropathological hallmark of AD, i.e. Aβ deposition, as measured with PiB PET imaging. Our findings show that community-dwelling cognitively normal older subjects with high amyloid load tend to be less confident than those with lower amyloid load about their general memory abilities when they compare their abilities to those of other people of the same age. Nevertheless, our high PiB subjects cannot be simply classified as “complainers” because they did not report that they were significantly “worse than other people”, but they are clearly dissimilar to their low PiB peers on their degree of self-confidence about memory abilities. Our results show that this more cautious self-report is not related to depressive affect or higher education. However, this feeling could reflect the experience of subtle memory limitations, which may indeed correspond to an objective memory weakness since subjects with high PiB uptake have lower performance than low PiB subjects on an episodic memory measure.
While the metacognition literature has repeatedly confirmed the multidimensional nature of monitoring processes[4749], an unexpected result is that PiB uptake was not significantly related to the other subjective cognition measures. In particular, it is surprising that subjects responded rather differently to the other off-line monitoring measure, when participants have to assess their memory abilities relative to 20 years ago. It is possible that the insidious and gradual occurrence of subtle cognitive problems may make an accurate monitoring of one’s abilities over time difficult in comparison to memory monitoring based on the present. For the on-line monitoring measure, subjects could be less prone to experience subtle cognitive limitations when they have to assess their ongoing performance in unfamiliar laboratory tasks.
Additionally, we found that regional PiB in the right medial PFC/ACC and precuneus/PCC/ICC was significantly related to general memory self-reports. These regions correspond precisely to those where amyloid load is typically the highest and the earliest, which confirms the consistency of the association of subjective cognition with the neuropathological signs of AD. Interestingly, these regions and their right hemispheric location are also commonly associated with the self and metacognitive processes[5052]. Nevertheless, the presence of amyloid in medial PFC/ACC and precuneus/PCC/ICC regions does not have detrimental effects on subjects’ insight about their cognition. Related to this, the impact of the regional amyloid load on local regional function is unclear in the literature.
The significant relationship observed between PiB uptake and subjective cognition measured with general memory self-reports relative to age-equivalent peers echoes previous studies showing that memory complaints in healthy people were related to genetic risks[25]and brain structural and functional features of AD[18,22]. In reference to the biomarker cascade model of AD proposed by Jack et al.[11]Aβ deposition measure in cognitively intact older subjects may be the most appropriate measure to detect the earliest manifestation of AD. While the two previous PiB studies involving SCI subjects were not conclusive about the association of PiB with SCI[28,29], our results are consistent with findings from postmortem investigations showing a relationship between memory complaints and AD pathology (including amyloid) in older people without dementia[26,27].
Our study provides new evidence that cognitively normal and non depressed older subjects with less confidence about their memory abilities may have neuropathological signs of AD. By extension, this observation is consistent with the idea that SCI may represent a very early clinical manifestation of incipient dementia, which supports the predictive validity of memory complaints for AD and the claim that SCI may constitute a “pre-MCI” stage[14]. Interestingly, a recent study[29]enriches the cascade model of AD proposed by Jack et al.[11]by showing that elevated PiB uptake was strongly related to brain atrophy in SCI, but not in MCI or in AD. Therefore, at the initial stage of AD development when amyloid accumulates and subtle neurodegeration begins, cognitive changes may be functionally compensated for and remain undetectable whereas subjective complaints may be present, i.e. the SCI stage. A probable duration of 15 years for the SCI stage has been proposed[53]. Then, amyloid deposition may reach a plateau, atrophy rates may accelerate and MCI may appear[11].
With regard to the interpretation of SCI in aging (SCI is often associated with affective or personality traits rather than dementia[54]), our results suggest that lower confidence about one’s memory in older subjects with intact cognition may not be a benign symptom and should be evaluated carefully since it may reflect an underlying degenerative process. These conclusions should be considered cautiously for several reasons. The present study is amongst the first to test the relationship between subjective cognition and an AD neuropathological hallmark, thus, replication studies are warranted. Whereas our high PiB subjects are less confident about their memory than low PiB subjects, they cannot be identified as “complainers”, and it is unclear whether similar results would be identified in SCI subjects. Furthermore, we did not assess the influence of personality features on metacognition, which may weight these relationships. Overall, relationships between subjective cognition and AD development should be clarified considering these limitations and with longitudinal follow-up of participants.
Acknowledgments
The authors thank all the participants from the study. This work was supported by a grant from the National Institute on Aging (AG027859), the Alzheimer’s Association (ZEN-08-87090), the Lavoisier grant from the French Ministry of Foreign and European Affairs, the France-Berkeley Fund, the Therese et Rene Planiol foundation, and the Societe de Neuropsychologie de Langue Francaise association.
1. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006;367(9518):1262–1270. [PubMed]
2. Jessen F, Wiese B, Bachmann C, et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. 2010;67(4):414–422. [PubMed]
3. Reisberg B, Prichep L, Mosconi L, et al. The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer’s disease. Alzheimers Dement. 2008;4(1 Suppl 1):S98–S108. [PubMed]
4. Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement. 2010;6(1):11–24. [PMC free article] [PubMed]
5. Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry. 2000;15(11):983–991. [PubMed]
6. van Oijen M, de Jong FJ, Hofman A, Koudstaal PJ, Breteler MMB. Subjective memory complaints, education, and risk of Alzheimer’s disease. Alzheimers Dement. 2007;3(2):92–97. [PubMed]
7. Comijs HC, Deeg DJH, Dik MG, Twisk JWR, Jonker C. Memory complaints; the association with psycho-affective and health problems and the role of personality characteristics. A 6-year follow-up study. J Affect Disord. 2002;72(2):157–165. [PubMed]
8. Jorm AF, Butterworth P, Anstey KJ, et al. Memory complaints in a community sample aged 60–64 years: associations with cognitive functioning, psychiatric symptoms, medical conditions, APOE genotype, hippocampus and amygdala volumes, and white-matter hyperintensities. Psychol Med. 2004;34(8):1495–1506. [PubMed]
9. Mott RT, Hulette CM. Neuropathology of Alzheimer’s disease. Neuroimaging Clin N Am. 2005;15(4):755–765. ix. [PubMed]
10. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–259. [PubMed]
11. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9(1):119–128. [PMC free article] [PubMed]
12. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319. [PubMed]
13. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718–1725. [PubMed]
14. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446–452. [PubMed]
15. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain. 2007;130(Pt 11):2837–2844. [PubMed]
16. Stewart R, Dufouil C, Godin O, et al. Neuroimaging correlates of subjective memory deficits in a community population. Neurology. 2008;70(18):1601–1607. [PubMed]
17. Striepens N, Scheef L, Wind A, et al. Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord. 2010;29(1):75–81. [PubMed]
18. van Norden AGW, Fick WF, de Laat KF, et al. Subjective cognitive failures and hippocampal volume in elderly with white matter lesions. Neurology. 2008;71(15):1152–1159. [PubMed]
19. Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging. 2006;27(12):1751–1756. [PubMed]
20. Wang PJ, Saykin AJ, Flashman LA, et al. Regionally specific atrophy of the corpus callosum in AD, MCI and cognitive complaints. Neurobiol Aging. 2006;27(11):1613–1617. [PMC free article] [PubMed]
21. Saykin AJ, Wishart HA, Rabin LA, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006;67(5):834–842. [PMC free article] [PubMed]
22. Ercoli L, Siddarth P, Huang S-C, et al. Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease. Arch Gen Psychiatry. 2006;63(4):442–448. [PubMed]
23. Mosconi L, De Santi S, Brys M, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry. 2008;63(6):609–618. [PMC free article] [PubMed]
24. Small GW, Chen ST, Komo S, et al. Memory self-appraisal in middle-aged and older adults with the apolipoprotein E-4 allele. Am J Psychiatry. 1999;156(7):1035–1038. [PubMed]
25. Stewart R, Russ C, Richards M, et al. Depression, APOE genotype and subjective memory impairment: a cross-sectional study in an African-Caribbean population. Psychol Med. 2001;31(3):431–440. [PubMed]
26. Barnes LL, Schneider JA, Boyle PA, Bienias JL, Bennett DA. Memory complaints are related to Alzheimer disease pathology in older persons. Neurology. 2006;67(9):1581–1585. [PMC free article] [PubMed]
27. Jorm AF, Masaki KH, Davis DG, et al. Memory complaints in nondemented men predict future pathologic diagnosis of Alzheimer disease. Neurology. 2004;63(10):1960–1961. [PubMed]
28. Rodda J, Okello A, Edison P, et al. (11)C-PIB PET in subjective cognitive impairment. Eur Psychiatry. 2010;25(2):123–125. [PubMed]
29. Chételat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta- amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67(3):317–324. [PubMed]
30. Flavell JH. Metacognition and cognitive monitoring: A new area of cognitive-developmental inquiry. Am Psychol. 1979;34:906–911.
31. Nelson TO, Narens L. Metamemory: A theoretical framework and new findings. In: Bower GH, editor. The psychology of learning and motivation: Advances in research and theory. New York: Academic Press; 1990. pp. 125–173.
32. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test. 2. San Antonio, TX: Psychological Corporation; 2000.
33. Wechsler D. Wechsler Memory Scale -Revised. San Antonio, TX: Psychological Corporation; 1987.
34. Stroop JP. Studies of inference in serial verbal reactions. J Exp Psychol. 1935;18:643–662.
35. Wechsler D. Wechsler Adult Intelligence Scale -Revised. San Antonio, TX: Psychological Corporation; 1987.
36. Salthouse TA, Babcock RL. Decomposing adult age differences in working memory. Dev Psychol. 1991;27(5):763–776.
37. Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia. 1968;6(1):53–60.
38. Mathis CA, Wang Y, Holt DP, et al. Synthesis and evaluation of 11C-labeled 6-substituted 2- arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46(13):2740–2754. [PubMed]
39. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834–840. [PubMed]
40. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528–1547. [PubMed]
41. Joachim CL, Mori H, Selkoe DJ. Amyloid beta-protein deposition in tissues other than brain in Alzheimer’s disease. Nature. 1989;341(6239):226–230. [PubMed]
42. Meltzer CC, Kinahan PE, Greer PJ, et al. Comparative evaluation of MR-based partial- volume correction schemes for PET. J Nucl Med. 1999;40(12):2053–2065. [PubMed]
43. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal- mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(Pt 5):1310–1323. [PMC free article] [PubMed]
44. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341–355. [PubMed]
45. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968–980. [PubMed]
46. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509–1517. [PMC free article] [PubMed]
47. Correa DD, Graves RE, Costa L. Awareness of memory deficit in Alzheimer’s disease patients and memory-impaired older adults. Aging Neuropsychol Cogn. 1996;3(3):215–228.
48. Duke LM, Seltzer B, Seltzer JE, Vasterling JJ. Cognitive components of deficit awareness in Alzheimer’s disease. Neuropsychology. 2002;16(3):359–369. [PubMed]
49. O’Keeffe FM, Dockree PM, Moloney P, Carton S, Robertson IH. Characterising error-awareness of attentional lapses and inhibitory control failures in patients with traumatic brain injury. Exp Brain Res. 2007;180(1):59–67. [PubMed]
50. Johnson SC, Baxter LC, Wilder LS, et al. Neural correlates of self-reflection. Brain. 2002;125(Pt 8):1808–1814. [PubMed]
51. Stuss DT, Picton TW, Alexander MP. Consciousness, self-awareness, and the frontal lobes. In: Salloway S, Malloy P, Duff JD, editors. The frontal lobes and neuropsychiatric illness. Washington, DC: American Psychiatric Pub; 2001. pp. 101–112.
52. Schmitz TW, Kawahara-Baccus TN, Johnson SC. Metacognitive evaluation, self-relevance, and the right prefrontal cortex. Neuroimage. 2004;22(2):941–947. [PubMed]
53. Prichep LS, John ER, Ferris SH, et al. Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imaging. Neurobiol Aging. 2006;27(3):471–481. [PubMed]
54. Bolla KI, Lindgren KN, Bonaccorsy C, Bleecker ML. Memory complaints in older adults. Fact or fiction? Arch Neurol. 1991;48(1):61–64. [PubMed]